AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival for the BTK inhibitor class in this cancer.
Copyright © 2024 | WordPress Theme by MH Themes